Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

Salvatore Del Prete (1) , Liliana Montella (1) , Michele Caraglia (2) , Luigi Maiorino (3) , Gregorio Cennamo (1) , Vincenzo Montesarchio (4) , Guido Piai (5) , Antonio Febbraro (6) , Luciano Tarantino (7) , Elena Capasso (8) , Giovannella Palmieri (9) , Rosario Guarrasi (1) , Maddalena Bianco (10) , Rosanna Mamone (11) , Clementina Savastano (12) , Agata Pisano (13) , Bruno Vincenzi (14) , Antonietta Sabia (15) , Alberto d'Agostino (16) , Vincenzo Faiola (1) , Raffaele Addeo (1)

1 Medical Oncology Unit
2 Department of Biochemistry and Biophysics
3 Oncology Unit “San Gennaro” Hospital
4 U.O.C - Medical Oncology “Cotugno” Hospital
5 AO San Sebastiano
6 Medical Oncology, Fatebenefratelli
7 Hepatology and Interventional Ultrasound Unit
8 Senology Unit
9 Department of Molecular and Clinical Endocrinology and Oncology
10 “San Leonardo” Hospital
11 Radiology and Diagnostic Imaging Unit “San Giovanni di Dio” Hospital
12 Medical Oncology “Ruggi d'Aragona” Hospital
13 Medical Oncology “S. Maria delle Grazie” Hospital
14 Medical Oncology Campus Biomedico
15 Medical Oncology Unit
16 Surgery Division Unit

Mots clés: Sorafenib; Long-acting octreotide; Hepatocellular carcinoma

Salvatore Del Prete, Liliana Montella, Michele Caraglia, Luigi Maiorino, Gregorio Cennamo, et al.. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemotherapy and Pharmacology, 2009, 66 (5), pp.837-844. ⟨10.1007/s00280-009-1226-z⟩. ⟨hal-00568278⟩